Compare OCFC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCFC | TRVI |
|---|---|---|
| Founded | 1902 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1996 | 2019 |
| Metric | OCFC | TRVI |
|---|---|---|
| Price | $16.74 | $13.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $21.42 | ★ $28.18 |
| AVG Volume (30 Days) | 1.1M | ★ 2.5M |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 0.27 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $47.45 | N/A |
| Revenue Next Year | $27.01 | N/A |
| P/E Ratio | $61.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.60 | $9.82 |
| 52 Week High | $20.61 | $20.22 |
| Indicator | OCFC | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 47.88 |
| Support Level | $16.16 | $13.08 |
| Resistance Level | $16.98 | $13.55 |
| Average True Range (ATR) | 0.36 | 0.67 |
| MACD | 0.16 | 0.18 |
| Stochastic Oscillator | 81.13 | 92.05 |
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.